phenytoin has been researched along with Drug Withdrawal Symptoms in 101 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The ESETT was a prospective, double-blinded, adaptive trial evaluating levetiracetam, valproate, and fosphenytoin as second-line agents in benzodiazepine-refractory status epilepticus in adults and children." | 9.51 | Treatment of Toxin-Related Status Epilepticus With Levetiracetam, Fosphenytoin, or Valproate in Patients Enrolled in the Established Status Epilepticus Treatment Trial. ( Chamberlain, JM; Coralic, Z; Kapur, J; Olson, KR; Overbeek, D; Silbergleit, R, 2022) |
| "To determine the effectiveness of IV phenytoin in the prevention of recurrent alcohol-related seizures during a six-hour observation period." | 9.07 | The lack of efficacy of phenytoin in the prevention of recurrent alcohol-related seizures. ( Bernstein, E; D'Onofrio, G; Fish, SS; Harrison, PM; Hossack, RW; Pickens, L; Rathlev, NK, 1994) |
| "Phenytoin does not show significant benefit over placebo in preventing recurrence of alcohol withdrawal seizures." | 9.07 | Emergency department treatment of alcohol withdrawal seizures with phenytoin. ( Chance, JF, 1991) |
| "To compare the temporal pattern of seizures after acute withdrawal of oxcarbazepine (OXC) and phenytoin (PHT) in the epilepsy monitoring unit (EMU)." | 7.74 | Temporal pattern of oxcarbazepine and phenytoin withdrawal seizures during epilepsy monitoring. ( Abou-Khalil, BW; Azar, NJ; Song, Y; Wang, L, 2008) |
| "The efficacy of phenytoin in the prevention of alcohol withdrawal seizures was studied in rats." | 7.66 | Prevention of alcohol withdrawal seizures with phenytoin in rats. ( Chu, NS, 1981) |
| "The ESETT was a prospective, double-blinded, adaptive trial evaluating levetiracetam, valproate, and fosphenytoin as second-line agents in benzodiazepine-refractory status epilepticus in adults and children." | 5.51 | Treatment of Toxin-Related Status Epilepticus With Levetiracetam, Fosphenytoin, or Valproate in Patients Enrolled in the Established Status Epilepticus Treatment Trial. ( Chamberlain, JM; Coralic, Z; Kapur, J; Olson, KR; Overbeek, D; Silbergleit, R, 2022) |
| "Phenytoin does not show significant benefit over placebo in preventing recurrence of alcohol withdrawal seizures." | 5.07 | Emergency department treatment of alcohol withdrawal seizures with phenytoin. ( Chance, JF, 1991) |
| "To determine the effectiveness of IV phenytoin in the prevention of recurrent alcohol-related seizures during a six-hour observation period." | 5.07 | The lack of efficacy of phenytoin in the prevention of recurrent alcohol-related seizures. ( Bernstein, E; D'Onofrio, G; Fish, SS; Harrison, PM; Hossack, RW; Pickens, L; Rathlev, NK, 1994) |
| "The effects of the withdrawal of phenytoin (PT) on cognitive and psychomotor functions of long-term patients in an epilepsy centre were studied." | 5.07 | Effects of withdrawal of phenytoin on cognitive and psychomotor functions in hospitalized epileptic patients on polytherapy. ( Bulmahn, A; May, TW; Rambeck, B; Wohlhüter, M, 1992) |
| "A prospective, double-blind, placebo-controlled investigation of possible withdrawal symptoms from phenytoin, carbamazepine and sodium valproate is reported in patients with active epilepsy, on combination therapy." | 5.06 | Withdrawal symptoms from phenytoin, carbamazepine and sodium valproate. ( Duncan, JS; Shorvon, SD; Trimble, MR, 1988) |
| " All the patients had epilepsy that had previously been untreated, and had been randomly assigned to receive carbamazepine, phenytoin, or sodium valproate." | 5.06 | Withdrawal of anticonvulsant drugs in patients free of seizures for two years. A prospective study. ( Callaghan, N; Garrett, A; Goggin, T, 1988) |
| "To compare the temporal pattern of seizures after acute withdrawal of oxcarbazepine (OXC) and phenytoin (PHT) in the epilepsy monitoring unit (EMU)." | 3.74 | Temporal pattern of oxcarbazepine and phenytoin withdrawal seizures during epilepsy monitoring. ( Abou-Khalil, BW; Azar, NJ; Song, Y; Wang, L, 2008) |
| " We studied the changes in arrhythmia profile and heart-rate variability, during abrupt withdrawal of carbamazepine and phenytoin treatment in 10 patients with side effects on these drugs." | 3.69 | Changes in arrhythmia profile and heart rate variability during abrupt withdrawal of antiepileptic drugs. Implications for sudden death. ( Bergfeldt, L; Ericson, M; Kennebäck, G; Tomson, T, 1997) |
| "Sodium phenobarbitone (20 and 70 mg/kg) had a significant anticonvulsant action against pentylenetetrazole-induced seizures, which persisted for 21 days of treatment." | 3.68 | Changes in seizure threshold and aggression during chronic treatment with three anticonvulsants and on drug withdrawal. ( File, SE; Wilks, LJ, 1990) |
| "Phenytoin has traditionally been used for both prophylaxis and acute treatment of alcohol withdrawal seizures." | 3.66 | Rational management of alcohol withdrawal seizures. ( Josephson, GW; Sabatier, HS, 1978) |
| "The efficacy of phenytoin in the prevention of alcohol withdrawal seizures was studied in rats." | 3.66 | Prevention of alcohol withdrawal seizures with phenytoin in rats. ( Chu, NS, 1981) |
| "A 49-year-old female with chronic alcoholism and epilepsy, treated with phenytoin, began to convulse when treatment with disulfiram (an inhibitor of phenytoin metabolism) was discontinued." | 3.65 | Multiple drug interactions with phenytoin. ( Birkett, DJ; Chinwah, PM; Graham, GG; Hickie, JB; Wade, DN, 1977) |
| " To test the validity of this primate model, the effects of diphenylhydantoin (DPH), phenobarbital, and primidone on spontaneous seizures evaluated for 8 months with a Latin-Squar experimental design." | 3.65 | Efficacy of standard anticonvulsants in monkey model with spontaneous motor seizures. ( DuCharme, LL; Farquhar, JA; Huntsman, BJ; Lockard, JS; Uhlir, V, 1975) |
| "The most important factor determining seizure recurrence was continued therapy, which was the case for barbiturates, phenytoin and valproate." | 2.69 | Does withdrawal of different antiepileptic drugs have different effects on seizure recurrence? Further results from the MRC Antiepileptic Drug Withdrawal Study. ( Chadwick, D, 1999) |
| "Seizures are commonly encountered in patients who do not have epilepsy." | 2.40 | Medical causes of seizures. ( Delanty, N; French, JA; Vaughan, CJ, 1998) |
| " In order to use these effectively, the critical care nurse must be aware of the indications and controversies surrounding their use, the patho-physiologic conditions that impact on the disposition, and appropriate dosing and monitoring of these agents in the critical care setting." | 2.38 | Anticonvulsants: pharmacotherapeutic issues in the critically ill patient. ( Dupuis, RE; Miranda-Massari, J, 1991) |
| "Carbamazepine was the most commonly used AED in 71." | 1.31 | Antiepileptic drug withdrawal in patients with temporal lobe epilepsy undergoing presurgical video-EEG monitoring. ( Chen, C; Guo, YC; Kwan, SY; Liu, LT; Shih, YH; Yen, DJ; Yiu, CH; Yu, HY, 2001) |
| " Drug was most often given on a fixed dosing schedule with additional medication "as needed" (52% of the programs)." | 1.29 | Alcohol withdrawal: a nationwide survey of inpatient treatment practices. ( Friedman, LS; Mayo-Smith, MF; Saitz, R, 1995) |
| " DPH withdrawal induced a leftward displacement of the dose-response curves obtained for the convulsive effects of both picrotoxin and metrazol and decreased the latency of 3-mercaptopropionic acid-induced seizures." | 1.27 | Central nervous system supersensitivity and withdrawal from long-term diphenylhydantoin treatment. ( De-Lima, TC; Palermo-Neto, J, 1983) |
| "However, as most alcohol withdrawal seizures occurred immediately before admission, the overall seizure incidence was higher (10%)." | 1.27 | Should alcohol withdrawal seizures be treated with anti-epileptic drugs? ( Hillbom, ME; Hjelm-Jäger, M, 1984) |
| "When phenytoin was being reduced, more seizures appeared to originate from the left temporal lobe than from the right." | 1.27 | Falsely localizing ictal onsets with depth EEG telemetry during anticonvulsant withdrawal. ( Crandall, PH; Engel, J, 1983) |
| "Spontaneous myoclonus in alcohol withdrawal is likely to represent diffuse cerebral hyperirritability during the withdrawal state." | 1.27 | Recurrent spontaneous myoclonus in alcohol withdrawal. ( Drake, ME, 1983) |
| " Dose-response curves for the convulsive effect of pentylenetetrazol obtained at the peak of the withdrawal signs shifted greatly to the left in alcohol withdrawn animals but less in barbital withdrawn animals." | 1.27 | Differentiation of alcohol and barbital physical dependence. ( Kaneda, H; Kaneto, H; Kawatani, S, 1986) |
| " The controls were comprised of naive rats (G-VI) and naive rats dosed in the same manner as the dependent rats." | 1.26 | Participant of serotonin turnover rate in the brain on barbital withdrawal convulsion. ( Hiramori, T; Nakao, K; Tagashira, E; Urano, T; Yanaura, S, 1982) |
| "Phenytoin was in effective for most withdrawal signs and some signs were made worse." | 1.26 | Evaluation of anticonvulsants in barbiturate withdrawal. ( Boisse, NR; Okamoto, M; Rosenberg, HC, 1977) |
| " Inter- and intra-subject variation in bioavailability was small (0." | 1.26 | Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics. ( Dumbrell, M; Khouw, V; Sandor, P; Sellers, EM, 1981) |
| " Methadone dosing adjustments should be anticipated when phenytoin is initiated or discontinued in methadone-maintained patients." | 1.26 | Phenytoin-induced methadone withdrawal. ( Benowitz, NL; Jaffery, NF; Kreek, MJ; Pond, SM; Tong, TG, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 71 (70.30) | 18.7374 |
| 1990's | 20 (19.80) | 18.2507 |
| 2000's | 8 (7.92) | 29.6817 |
| 2010's | 1 (0.99) | 24.3611 |
| 2020's | 1 (0.99) | 2.80 |
| Authors | Studies |
|---|---|
| Coralic, Z | 1 |
| Kapur, J | 1 |
| Olson, KR | 1 |
| Chamberlain, JM | 1 |
| Overbeek, D | 1 |
| Silbergleit, R | 1 |
| Wang, L | 3 |
| Wang, X | 1 |
| Shi, X | 1 |
| Qiu, W | 1 |
| Miao, A | 1 |
| ESSIG, CF | 1 |
| CARTER, WW | 1 |
| AYCRIGG, JB | 1 |
| Cramer, JA | 1 |
| Hammer, AE | 1 |
| Kustra, RP | 1 |
| Black, JA | 1 |
| Liu, S | 1 |
| Carrithers, M | 1 |
| Carrithers, LM | 1 |
| Waxman, SG | 1 |
| Kulkarni, J | 1 |
| McCauley-Elsom, K | 1 |
| Marston, N | 1 |
| Gilbert, H | 1 |
| Gurvich, C | 1 |
| de Castella, A | 1 |
| Fitzgerald, P | 1 |
| Azar, NJ | 2 |
| Song, Y | 2 |
| Abou-Khalil, BW | 2 |
| Wright, AT | 1 |
| Tagashira, E | 2 |
| Hiramori, T | 2 |
| Urano, T | 2 |
| Nakao, K | 2 |
| Yanaura, S | 2 |
| Alphs, L | 1 |
| Davis, JM | 1 |
| Koch, S | 1 |
| Göpfert-Geyer, I | 1 |
| Jäger-Roman, E | 1 |
| Jakob, S | 1 |
| Huth, H | 1 |
| Hartmann, A | 1 |
| Rating, D | 1 |
| Helge, H | 1 |
| Roman, EJ | 1 |
| Buchanan, N | 1 |
| Lambert, JB | 1 |
| Barrah, N | 1 |
| De-Lima, TC | 1 |
| Palermo-Neto, J | 1 |
| Hillbom, ME | 1 |
| Hjelm-Jäger, M | 1 |
| De Lima, TC | 1 |
| Palermo Neto, J | 1 |
| Aminoff, MJ | 1 |
| Wilbur, R | 1 |
| Kulik, FA | 1 |
| Engel, J | 1 |
| Crandall, PH | 1 |
| Drake, ME | 1 |
| Davis, VJ | 2 |
| Chu, NS | 1 |
| Tong, TG | 1 |
| Pond, SM | 1 |
| Kreek, MJ | 1 |
| Jaffery, NF | 1 |
| Benowitz, NL | 1 |
| Spencer, SS | 1 |
| Spencer, DD | 1 |
| Williamson, PD | 1 |
| Mattson, RH | 1 |
| Sandor, P | 1 |
| Sellers, EM | 3 |
| Dumbrell, M | 1 |
| Khouw, V | 1 |
| Poling, AD | 1 |
| Wysocki, T | 1 |
| Breuning, SE | 1 |
| Everett, G | 1 |
| Evans, AN | 1 |
| Brooke, OG | 1 |
| West, RJ | 1 |
| Tonnby, B | 1 |
| Nilsson, HL | 1 |
| Aldenkamp, AP | 1 |
| Alpherts, WC | 1 |
| Blennow, G | 1 |
| Elmqvist, D | 1 |
| Heijbel, J | 1 |
| Sandstedt, P | 1 |
| Wåhlander, L | 1 |
| Wosse, E | 1 |
| Rathlev, NK | 1 |
| D'Onofrio, G | 1 |
| Fish, SS | 1 |
| Harrison, PM | 1 |
| Bernstein, E | 1 |
| Hossack, RW | 1 |
| Pickens, L | 1 |
| Evans, EB | 1 |
| Balster, RL | 1 |
| Saitz, R | 1 |
| Friedman, LS | 1 |
| Mayo-Smith, MF | 1 |
| Knoll, B | 1 |
| Haefeli, WE | 1 |
| Ladewig, D | 1 |
| Stohler, R | 1 |
| Noachtar, S | 1 |
| Kennebäck, G | 1 |
| Ericson, M | 1 |
| Tomson, T | 1 |
| Bergfeldt, L | 1 |
| Delanty, N | 1 |
| Vaughan, CJ | 1 |
| French, JA | 1 |
| Sagduyu, A | 1 |
| Tarlaci, S | 1 |
| Sirin, H | 1 |
| Chadwick, D | 1 |
| Shad, MU | 1 |
| Preskorn, SH | 1 |
| Colombo-Arnet, E | 1 |
| Yen, DJ | 1 |
| Chen, C | 1 |
| Shih, YH | 1 |
| Guo, YC | 1 |
| Liu, LT | 1 |
| Yu, HY | 1 |
| Kwan, SY | 1 |
| Yiu, CH | 1 |
| Covington, EC | 1 |
| Anderson, GD | 1 |
| Gidal, BE | 1 |
| Messenheimer, JA | 1 |
| Gilliam, FG | 1 |
| Koch-Weser, J | 1 |
| Kalant, H | 1 |
| Smith, RF | 1 |
| Ludwig, BI | 1 |
| Marsan, CA | 1 |
| Olbrich, R | 1 |
| Iber, FL | 2 |
| Brzeczko, A | 1 |
| Press, AW | 1 |
| Kirby, S | 1 |
| Cruess, DF | 1 |
| Adir, J | 1 |
| Okamoto, M | 1 |
| Rosenberg, HC | 1 |
| Boisse, NR | 1 |
| Birkett, DJ | 1 |
| Graham, GG | 1 |
| Chinwah, PM | 1 |
| Wade, DN | 1 |
| Hickie, JB | 1 |
| Josephson, GW | 1 |
| Sabatier, HS | 1 |
| Robertson, CC | 1 |
| Lockard, JS | 2 |
| DuCharme, LL | 2 |
| Congdon, WC | 1 |
| Franklin, SC | 1 |
| Sprague, GL | 1 |
| Craigmill, AL | 1 |
| Vincent, TS | 1 |
| Uhlir, V | 1 |
| Farquhar, JA | 1 |
| Huntsman, BJ | 1 |
| Peichev, L | 2 |
| May, TW | 1 |
| Bulmahn, A | 1 |
| Wohlhüter, M | 1 |
| Rambeck, B | 1 |
| Lucas, RE | 1 |
| Montgomery, WS | 1 |
| Piepho, R | 1 |
| Whelton, A | 1 |
| Mayor, G | 1 |
| Neu, H | 1 |
| Laddu, A | 1 |
| Dupuis, RE | 1 |
| Miranda-Massari, J | 1 |
| Chance, JF | 1 |
| File, SE | 1 |
| Wilks, LJ | 1 |
| Saxon, AJ | 1 |
| Whittaker, S | 1 |
| Hawker, CS | 1 |
| Bromfield, EB | 1 |
| Dambrosia, J | 1 |
| Devinsky, O | 1 |
| Nice, FJ | 1 |
| Theodore, WH | 1 |
| Aman, MG | 1 |
| Singh, NN | 1 |
| Karler, R | 1 |
| Calder, LD | 1 |
| Turkanis, SA | 1 |
| Callaghan, N | 1 |
| Garrett, A | 1 |
| Goggin, T | 1 |
| Duncan, JS | 1 |
| Shorvon, SD | 1 |
| Trimble, MR | 1 |
| Gallassi, R | 1 |
| Morreale, A | 1 |
| Lorusso, S | 1 |
| Ferrari, M | 1 |
| Procaccianti, G | 1 |
| Lugaresi, E | 1 |
| Baruzzi, A | 1 |
| Kaneto, H | 1 |
| Kawatani, S | 1 |
| Kaneda, H | 1 |
| Edwards, VE | 2 |
| Gardner, AJ | 1 |
| Mellor, CS | 1 |
| Kamei, C | 1 |
| Shimomura, K | 1 |
| Ueki, S | 1 |
| Covi, L | 1 |
| Lipman, RS | 1 |
| Pattison, JH | 1 |
| Derogatis, LR | 1 |
| Uhlenhuth, EH | 1 |
| Eadie, MJ | 1 |
| Sampliner, R | 1 |
| Overall, JE | 1 |
| Brown, D | 1 |
| Williams, JD | 1 |
| Neill, LT | 1 |
| Frost, JB | 1 |
| Rothstein, E | 1 |
| Hill, RM | 1 |
| Verniaud, WM | 1 |
| Horning, MG | 1 |
| McCulley, LB | 1 |
| Morgan, NF | 1 |
| Gessner, PK | 3 |
| Fertziger, AP | 1 |
| Lynch, JJ | 1 |
| Stein, E | 1 |
| Rosenblum, JA | 2 |
| Shafer, N | 1 |
| Finer, MJ | 2 |
| Adams, HP | 1 |
| Madden, JS | 1 |
| Jones, D | 1 |
| Frisch, EP | 2 |
| Glatt, MM | 1 |
| George, HR | 1 |
| Smith, DE | 1 |
| Wesson, DR | 1 |
| Kane, FJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Blinded, Comparative Effectiveness Study of Fosphenytoin, Valproic Acid, or Levetiracetam in the Emergency Department Treatment of Patients With Benzodiazepine-refractory Status Epilepticus.[NCT01960075] | Phase 3 | 478 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| OxCarbazepine as a Neuroprotective Agent in MS: A Phase 2a Trial[NCT02104661] | Phase 2 | 30 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| Phenobarbital Versus Ativan for Refractory Alcohol Withdrawal Treatment in the Intensive Care Unit[NCT04156464] | Phase 4 | 142 participants (Anticipated) | Interventional | 2020-07-06 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Length of hospital stay in days (NCT01960075)
Timeframe: length of hospital stay
| Intervention | days (Median) |
|---|---|
| Fosphenytoin (FOS) | 3 |
| Valproic Acid | 3 |
| Levetiracetam | 3 |
Length of stay is determined by the number of calendar days after the day of ED arrival until hospital discharge or subject end-of-study. (NCT01960075)
Timeframe: number of calendar days after the day of ED arrival until hospital discharge or subject end-of-study
| Intervention | days (Median) |
|---|---|
| Fosphenytoin (FOS) | 1 |
| Valproic Acid | 1 |
| Levetiracetam | 1 |
The time to termination of seizures is the interval from the start of study drug infusion to cessation of clinically apparent seizure in those who meet the primary outcome. (NCT01960075)
Timeframe: start of drug infusion to seizure cessation
| Intervention | minutes (Median) |
|---|---|
| Fosphenytoin (FOS) | 11.7 |
| Valproic Acid | 7.0 |
| Levetiracetam | 10.5 |
ICU admission is recorded as occurring only if the ICU is the initial inpatient unit for the patient. (NCT01960075)
Timeframe: Admission to intensive care unit after start of study drug infusion, where the ICU is the initial inpatient unit for the patient
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 70 |
| Valproic Acid | 71 |
| Levetiracetam | 87 |
Determined by the absence of clinically apparent seizures and improving consciousness at 1 hour without other anticonvulsant medications. The Adjudicated outcomes analysis is different from Outcome measure 1 because a central clinical phenomenology core of four neurologists adjudicated from the medical records the time to seizure cessation, the time in status epilepticus before trial-drug initiation, and the cause of the seizure. For each enrollment, two neurologists from this core group conducted independent initial reviews and then determined a consensus or consulted a third adjudicator, as needed. Adjudicators were unaware of the treatment assignments and made determinations by medical record review. (NCT01960075)
Timeframe: Within 60 minutes after the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 57 |
| Valproic Acid | 60 |
| Levetiracetam | 67 |
Determined by the absence of clinically apparent seizures and improving consciousness at 1 hour without other anticonvulsant medications. Intention to treat (NCT01960075)
Timeframe: Within 60 minutes after the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 53 |
| Valproic Acid | 56 |
| Levetiracetam | 68 |
Determined by the absence of clinically apparent seizures and improving consciousness at 1 hour without other anticonvulsant medications. Per-protocol analysis (NCT01960075)
Timeframe: Within 60 minutes after the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 37 |
| Valproic Acid | 43 |
| Levetiracetam | 51 |
Acute anaphylaxis is defined as a clinical presentation consistent with life threatening allergic reaction occurring within 6 hours of the start of study drug infusions and manifested as urticaria in combination with either (1) a systolic blood pressure of < 90 mmHg sustained for greater than 5 minutes, or (2) objective evidence of airway obstruction, and for which the patient was treated with antihistamines and/or steroids. (NCT01960075)
Timeframe: within 6 hours of the start of study drug infusions
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 0 |
| Levetiracetam | 0 |
Respiratory depression is defined as impairment of ventilation or oxygenation necessitating definitive endotracheal intubation and mechanical ventilation. It is distinct from intubations performed only for airway protection in those with decreased levels of consciousness. It does not include those getting only supraglottic airways or transient bag-valve-mask support. (NCT01960075)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 16 |
| Valproic Acid | 10 |
| Levetiracetam | 12 |
acute seizure recurrence 60 minutes to 12 hours after start of study drug infusion (NCT01960075)
Timeframe: 60 minutes to 12 hours after start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 14 |
| Valproic Acid | 14 |
| Levetiracetam | 16 |
Safety outcome: Death (NCT01960075)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 3 |
| Valproic Acid | 2 |
| Levetiracetam | 7 |
Endotracheal intubation within 60 minutes of start of study drug infusion (NCT01960075)
Timeframe: within 60 minutes of start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 33 |
| Valproic Acid | 21 |
| Levetiracetam | 30 |
Safety outcome: Hepatic transaminase or ammonia elevations (NCT01960075)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 1 |
| Levetiracetam | 1 |
Life-threatening hypotension within 60 minutes of the start of study drug infusion (NCT01960075)
Timeframe: within 60 minutes of the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 4 |
| Valproic Acid | 2 |
| Levetiracetam | 1 |
Life-threatening cardiac arrhythmia within 60 minutes of the start of study drug infusion (NCT01960075)
Timeframe: within 60 minutes of the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 0 |
| Levetiracetam | 1 |
Purple glove syndrome is defined as the presence of all three of the findings of the objective edema: discoloration, and pain in the distal extremity in which study drug was administered, with or without known extravasation, and for which there is no other evident etiology. (NCT01960075)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 0 |
| Levetiracetam | 0 |
Number of participants with seizure cessation within 20 minutes of study drug initiation for patients with treatment success. This outcome measure was only reported in the Supplementary materials to the Primary Paper. (NCT01960075)
Timeframe: within 20 minutes
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 43 |
| Valproic Acid | 43 |
| Levetiracetam | 53 |
5 reviews available for phenytoin and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Anticonvulsant drugs in alcohol withdrawal: use of phenytoin, primidone, carbamazepine, valproic acid, and the sedative anticonvulsants.
Topics: Alcoholism; Anticonvulsants; Carbamazepine; Humans; Hypnotics and Sedatives; Phenytoin; Primidone; S | 1981 |
Medical causes of seizures.
Topics: Acute Kidney Injury; Anticonvulsants; Antitubercular Agents; Blood Pressure; Brain Diseases; Broncho | 1998 |
Anticonvulsants for neuropathic pain and detoxification.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Clonazepam; Cyclohexanecarboxylic Acids; Gabapenti | 1998 |
Alcohol intoxication and withdrawal.
Topics: Acute Disease; Alcohol Withdrawal Delirium; Alcoholic Intoxication; Antipsychotic Agents; Barbiturat | 1976 |
Anticonvulsants: pharmacotherapeutic issues in the critically ill patient.
Topics: Anticonvulsants; Benzodiazepines; Brain Injuries; Carbamazepine; Central Nervous System Diseases; Ep | 1991 |
17 trials available for phenytoin and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Treatment of Toxin-Related Status Epilepticus With Levetiracetam, Fosphenytoin, or Valproate in Patients Enrolled in the Established Status Epilepticus Treatment Trial.
Topics: Adult; Alcoholism; Analgesics, Opioid; Anticonvulsants; Benzodiazepines; Child; Cocaine; Female; Hum | 2022 |
Quality of life improvement with conversion to lamotrigine monotherapy.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Drug Therapy, Combination; Electroencephalography | 2004 |
[Anti-epileptic agents during pregnancy. A prospective study on the course of pregnancy, malformations and child development].
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Akathisia, Drug-Induced; Anencephaly; Ant | 1983 |
Withdrawal of antiepileptic medication in children. Correlation of cognitive function and plasma concentration--the multicentre 'Holmfrid' study.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Cognition; Humans; Phenytoin; Substance Withdrawa | 1994 |
The lack of efficacy of phenytoin in the prevention of recurrent alcohol-related seizures.
Topics: Adult; Alcoholism; Chi-Square Distribution; Double-Blind Method; Ethanol; Female; Humans; Male; Phen | 1994 |
Does withdrawal of different antiepileptic drugs have different effects on seizure recurrence? Further results from the MRC Antiepileptic Drug Withdrawal Study.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Child; Drug Combinations; Epilepsy; Female; Human | 1999 |
Time course of lamotrigine de-induction: impact of step-wise withdrawal of carbamazepine or phenytoin.
Topics: Adolescent; Adult; Aged; Carbamazepine; Dose-Response Relationship, Drug; Drug Therapy, Combination; | 2002 |
Effects of withdrawal of phenytoin on cognitive and psychomotor functions in hospitalized epileptic patients on polytherapy.
Topics: Adult; Anticonvulsants; Attention; Cognition; Dose-Response Relationship, Drug; Drug Therapy, Combin | 1992 |
Emergency department treatment of alcohol withdrawal seizures with phenytoin.
Topics: Double-Blind Method; Emergencies; Ethanol; Humans; Phenytoin; Prospective Studies; Recurrence; Seizu | 1991 |
Withdrawal of anticonvulsant drugs in patients free of seizures for two years. A prospective study.
Topics: Adult; Analysis of Variance; Anticonvulsants; Carbamazepine; Electroencephalography; Epilepsies, Par | 1988 |
Withdrawal symptoms from phenytoin, carbamazepine and sodium valproate.
Topics: Adolescent; Adult; Aged; Carbamazepine; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, | 1988 |
Length of treatment with anxiolytic sedatives and response to their sudden withdrawal.
Topics: Adolescent; Adult; Aged; Anxiety; Chlordiazepoxide; Clinical Trials as Topic; Drug Tolerance; Female | 1973 |
Clonazepam--a clinical study of its effectiveness as an anticonvulsant.
Topics: Adolescent; Adult; Anticonvulsants; Benzodiazepinones; Child; Child, Preschool; Chlorobenzenes; Clin | 1973 |
Diphenylhydantoin control of alcohol withdrawal seizures. Results of a controlled study.
Topics: Administration, Oral; Alcoholism; Chlordiazepoxide; Clinical Trials as Topic; Drug Evaluation; Elect | 1974 |
Drug treatment of anxiety and depression in detoxified alcoholic patients.
Topics: Alcoholism; Amitriptyline; Analysis of Variance; Anxiety; Ascorbic Acid; Chlordiazepoxide; Depressio | 1973 |
Treatment of alcohol withdrawal syndromes.
Topics: Chloral Hydrate; Chlordiazepoxide; Clinical Trials as Topic; Diazepam; Drug Synergism; Ethanol; Huma | 1971 |
Evaluation of chlormethiazole in treatment for alcohol withdrawal syndrome. Results of a controlled trial.
Topics: Alcoholism; Chlormethiazole; Clinical Trials as Topic; Depression; Female; Humans; Hypertension; Hyp | 1966 |
79 other studies available for phenytoin and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Reversible lesion involving the splenium of the corpus callosum caused by phenytoin sodium withdrawal.
Topics: Anticonvulsants; Brain Diseases; Corpus Callosum; Diagnosis, Differential; Epilepsy; Humans; Male; M | 2017 |
Failure of diphenylhydantoin in preventing barbiturate withdrawal convulsions in the dog.
Topics: Animals; Barbiturates; Dogs; Hydantoins; Phenytoin; Seizures; Substance Withdrawal Syndrome | 1962 |
TWO CASES OF WITHDRAWAL FROM ETHCHLORVYNOL.
Topics: Chlorpromazine; Delirium; Epilepsy, Tonic-Clonic; Ethchlorvynol; Hallucinations; Hypnotics and Sedat | 1964 |
Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine.
Topics: Animals; Anticonvulsants; Antigens, CD; Axons; Carbamazepine; Cell Count; Disease Models, Animal; En | 2007 |
Preliminary findings from the National Register of Antipsychotic Medication in Pregnancy.
Topics: Adult; Antipsychotic Agents; Australia; Benzodiazepines; Chlorpromazine; Cross-Sectional Studies; Da | 2008 |
Temporal pattern of oxcarbazepine and phenytoin withdrawal seizures during epilepsy monitoring.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Case-Control Studies; Electroencephalography; Epi | 2008 |
Generalized tonic-clonic seizures after acute oxcarbazepine withdrawal.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Male; Middle Aged; Oxca | 2008 |
Enhancement of drug withdrawal convulsion by combinations of phenobarbital and antipsychotic agents.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Drug Combinations; Drug Tolerance; Humans; Male; Ph | 1981 |
Noncatecholaminergic treatments of tardive dyskinesia.
Topics: Amantadine; Anti-Anxiety Agents; Benzodiazepines; Cyproheptadine; D-Ala(2),MePhe(4),Met(0)-ol-enkeph | 1982 |
Participant of serotonin turnover rate in the brain on barbital withdrawal convulsion.
Topics: Animals; Barbital; Barbiturates; Brain; Chlorpromazine; Humans; Hydroxyindoleacetic Acid; Male; Nitr | 1982 |
Rationalisation of therapy in severe epilepsy.
Topics: Adult; Anticonvulsants; Arousal; Atrophy; Cerebellum; Drug Administration Schedule; Drug Therapy, Co | 1983 |
Central nervous system supersensitivity and withdrawal from long-term diphenylhydantoin treatment.
Topics: Animals; Convulsants; Dose-Response Relationship, Drug; Drug Hypersensitivity; Humans; Male; Phenyto | 1983 |
Should alcohol withdrawal seizures be treated with anti-epileptic drugs?
Topics: Adult; Aged; Alcohol Withdrawal Delirium; Alcoholism; Anticonvulsants; Carbamazepine; Chlormethiazol | 1984 |
The effects of diphenylhydantoin on rat behavior.
Topics: Animals; Behavior, Animal; Dose-Response Relationship, Drug; Humans; Male; Phenytoin; Rats; Substanc | 1980 |
Drug treatment of epilepsy.
Topics: Anticonvulsants; Carbamazepine; Clonazepam; Electroencephalography; Epilepsy; Ethosuximide; Female; | 1981 |
Falsely localizing ictal onsets with depth EEG telemetry during anticonvulsant withdrawal.
Topics: Adult; Electroencephalography; Epilepsy; Humans; Male; Meningeal Neoplasms; Meningioma; Phenytoin; S | 1983 |
Recurrent spontaneous myoclonus in alcohol withdrawal.
Topics: Adult; Aged; Diagnosis, Differential; Drug Therapy, Combination; Electrocardiography; Ethanol; Femal | 1983 |
Effects of phenytoin withdrawal on matching to sample and workshop performance of mentally retarded individuals--a brief report.
Topics: Adolescent; Adult; Discrimination, Psychological; Female; Humans; Intellectual Disability; Male; Phe | 1982 |
Prevention of alcohol withdrawal seizures with phenytoin in rats.
Topics: Acoustic Stimulation; Alcoholism; Animals; Female; Humans; Male; Phenytoin; Rats; Seizures; Substanc | 1981 |
Phenytoin-induced methadone withdrawal.
Topics: Adult; Drug Administration Schedule; Drug Interactions; Humans; Male; Methadone; Phenytoin; Pyrrolid | 1981 |
Ictal effects of anticonvulsant medication withdrawal in epileptic patients.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Electroencephalography; Epilepsy; Humans; Middle | 1981 |
Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.
Topics: Administration, Oral; Adult; Alcoholism; Biological Availability; Ethanol; Humans; Injections, Intra | 1981 |
Effects of phenytoin withdrawal on matching to sample and workshop performance of mentally retarded persons.
Topics: Adolescent; Adult; Color Perception; Discrimination Learning; Epilepsy; Female; Humans; Intellectual | 1981 |
Alcohol withdrawal syndrome: prevention and treatment.
Topics: Administration, Oral; Alcohol Drinking; Alcohol Withdrawal Delirium; Benzodiazepines; Ethanol; Human | 1981 |
The ingestion by pregnant women of substances toxic to the foetus.
Topics: Abnormalities, Drug-Induced; Barbiturates; Clitoris; Diazepam; Disorders of Sex Development; Doxylam | 1980 |
Inhaled 1,1,1-trichloroethane-produced physical dependence in mice: effects of drugs and vapors on withdrawal.
Topics: Administration, Inhalation; Animals; Chlorpromazine; Ethanol; Male; Mice; Midazolam; Pentobarbital; | 1993 |
Alcohol withdrawal: a nationwide survey of inpatient treatment practices.
Topics: Adrenergic beta-Antagonists; Alcoholism; Barbiturates; Benzodiazepines; Chlordiazepoxide; Clonidine; | 1995 |
Early recurrence of withdrawal symptoms under phenytoin and chronic alcohol use.
Topics: Adult; Alcoholism; Epilepsy, Generalized; Humans; Male; Methadone; Opioid-Related Disorders; Phenyto | 1997 |
Bilateral fractures of the proximal humerus: a rare non-traumatic complication of generalized tonic-clonic seizures following withdrawal of antiepileptic medication.
Topics: Anticonvulsants; Epilepsy, Tonic-Clonic; Humans; Humeral Fractures; Male; Middle Aged; Phenytoin; Su | 1998 |
Changes in arrhythmia profile and heart rate variability during abrupt withdrawal of antiepileptic drugs. Implications for sudden death.
Topics: Adult; Aged; Analysis of Variance; Anticonvulsants; Arrhythmias, Cardiac; Autonomic Nervous System; | 1997 |
Generalized tonic-clonic status epilepticus: causes, treatment, complications and predictors of case fatality.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Demography; Diazepam; Epilepsy, Tonic-Clonic; Femal | 1998 |
Drug-drug interaction in reverse: possible loss of phenytoin efficacy as a result of fluoxetine discontinuation.
Topics: Adult; Anticonvulsants; Drug Interactions; Epilepsy, Tonic-Clonic; Fluoxetine; Humans; Male; Phenyto | 1999 |
[Phenytoin-induced hypersensitivity reaction with liver failure].
Topics: Anticonvulsants; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Administration Sche | 2000 |
Antiepileptic drug withdrawal in patients with temporal lobe epilepsy undergoing presurgical video-EEG monitoring.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Electroencephalography; Epilepsy, Complex Partial | 2001 |
Relative effectiveness of primidone (Mysoline) and diphenylhydantoin (Dilantin) in the management of sedative withdrawal seizures.
Topics: Antipsychotic Agents; Chlordiazepoxide; Drug Evaluation; Humans; Phenothiazines; Phenytoin; Primidon | 1976 |
EEG changes after withdrawal of medication in epileptic patients.
Topics: Adult; Anticonvulsants; Brain; Electroencephalography; Epilepsy; Humans; Phenobarbital; Phenytoin; P | 1975 |
[Epilepsy? Withdrawl symptoms and alcoholic hepatitis].
Topics: Chlormethiazole; Diagnosis, Differential; Diazepam; Epilepsy, Tonic-Clonic; Hepatitis, Alcoholic; Hu | 1978 |
Alcohol withdrawal states and the need for treatment.
Topics: Adult; Alcoholism; Chlormethiazole; Drug Therapy, Combination; Emergencies; Female; Haloperidol; Hum | 1979 |
Comparison of steady state phenytoin metabolism in alcoholic immediately after drinking ceases and three weeks later.
Topics: Adult; Alcoholism; Humans; Kinetics; Male; Middle Aged; Phenytoin; Substance Withdrawal Syndrome | 1979 |
Evaluation of anticonvulsants in barbiturate withdrawal.
Topics: Animals; Anticonvulsants; Behavior, Animal; Cats; Dimethadione; Female; Humans; Male; Pentobarbital; | 1977 |
Multiple drug interactions with phenytoin.
Topics: Alcoholism; Disulfiram; Epilepsy; Female; Humans; Middle Aged; Phenytoin; Substance Withdrawal Syndr | 1977 |
Rational management of alcohol withdrawal seizures.
Topics: Alcoholism; Anticonvulsants; Humans; Phenytoin; Recurrence; Seizures; Substance Withdrawal Syndrome | 1978 |
Alcohol intoxication and the alcohol withdrawal syndrome.
Topics: Alcoholic Intoxication; Alcoholism; Benzodiazepines; Chlordiazepoxide; Hallucinations; Humans; Pheny | 1978 |
Prophylaxis with diphenylhydantoin and phenobarbital in alumina-gel monkey model. II. Fourth-month follow-up period: seizure, EEG, blood and behavioral data.
Topics: Aluminum Hydroxide; Animals; Behavior, Animal; Disease Models, Animal; Drug Evaluation, Preclinical; | 1976 |
Control of ethanol withdrawal symptoms in mice by phenytoin.
Topics: Animals; Disease Models, Animal; Ethanol; Humans; Male; Mice; Pharmaceutical Vehicles; Phenytoin; Py | 1976 |
Dilantin in the treatment of alcoholism.
Topics: Alcohol Withdrawal Delirium; Alcoholic Intoxication; Alcoholism; Humans; Phenytoin; Substance Withdr | 1975 |
Efficacy of standard anticonvulsants in monkey model with spontaneous motor seizures.
Topics: Aluminum; Animals; Anticonvulsants; Disease Models, Animal; Electroencephalography; Feeding Behavior | 1975 |
Letter: Treatment of ethanol intoxication.
Topics: Alcoholism; Epilepsy; Humans; Phenytoin; Substance Withdrawal Syndrome | 1976 |
Mechanisms of neurotransmission of valproate sodium in suppressing barbiturate and phenytoin withdrawal syndrome.
Topics: Animals; Barbiturates; Brain; Neurotransmitter Agents; Phenytoin; Rats; Rats, Wistar; Substance With | 1992 |
Suppression of experimental barbiturate and phenytoin withdrawal syndrome using valproate sodium.
Topics: Animals; Barbiturates; Male; Phenytoin; Rats; Rats, Wistar; Seizures; Substance Withdrawal Syndrome; | 1992 |
Glutethimide withdrawal syndrome--the ethics of supply and demand.
Topics: Aged; Glutethimide; Humans; Male; Phenytoin; Seizures; Substance Withdrawal Syndrome | 1992 |
Grand mal status epilepticus.
Topics: Alcoholism; Anticonvulsants; Diazepam; Epilepsy, Tonic-Clonic; Ethanol; Humans; Lorazepam; Male; Mid | 1992 |
Changes in seizure threshold and aggression during chronic treatment with three anticonvulsants and on drug withdrawal.
Topics: Aggression; Animals; Anticonvulsants; Lorazepam; Male; Mice; Pentylenetetrazole; Phenobarbital; Phen | 1990 |
Valproic acid, unlike other anticonvulsants, has no effect on methadone metabolism: two cases.
Topics: Adult; Drug Therapy, Combination; Heroin Dependence; Humans; Male; Methadone; Middle Aged; Phenytoin | 1989 |
Phenytoin withdrawal and seizure frequency.
Topics: Adult; Carbamazepine; Diazepam; Drug Therapy, Combination; Epilepsy; Epilepsy, Temporal Lobe; Female | 1989 |
A critical appraisal of recent drug research in mental retardation: the Coldwater studies.
Topics: Aggression; Antipsychotic Agents; Attitude of Health Personnel; Discrimination Learning; Humans; Ins | 1986 |
Prolonged CNS hyperexcitability in mice after a single exposure to delta-9-tetrahydrocannabinol.
Topics: Animals; Central Nervous System; Dronabinol; Drug Tolerance; Electroshock; Male; Mice; Phenobarbital | 1986 |
Cognitive effects of phenytoin during monotherapy and after withdrawal.
Topics: Adult; Attention; Cognition; Epilepsy; Humans; Middle Aged; Neuropsychological Tests; Phenytoin; Psy | 1987 |
Differentiation of alcohol and barbital physical dependence.
Topics: Animals; Barbital; Barbiturates; Diazepam; Ethanol; Ethosuximide; Male; Mice; Morphine; Naloxone; Pe | 1986 |
Side effects of clonazepam therapy.
Topics: Adolescent; Adult; Aggression; Ataxia; Benzodiazepinones; Clonazepam; Drug Interactions; Epilepsy; E | 1974 |
Neuropathy after alcohol withdrawal.
Topics: Adult; Alcoholism; Female; Folic Acid; Humans; Male; Middle Aged; Peripheral Nervous System Diseases | 1972 |
Anticonvulsant drugs in idiopathic epilepsy.
Topics: Acetazolamide; Anticonvulsants; Epilepsy; Epilepsy, Absence; Ethosuximide; Humans; Hydantoins; Mepho | 1970 |
Sedation threshold and sedation recovery time in alcoholics.
Topics: Adult; Alcoholism; Amobarbital; Attention; Chloral Hydrate; Chlorpromazine; Differential Threshold; | 1974 |
Significance of withdrawal jumping response in predicting physical dependence in mice.
Topics: Amitriptyline; Animals; Atropine; Cannabis; Chlordiazepoxide; Chlorpromazine; Diazepam; Humans; Imip | 1973 |
Mesoridazine and chlorpromazine in the treatment of alcohol withdrawal syndrome.
Topics: Administration, Oral; Alcoholism; Chlorpromazine; Female; Humans; Injections, Intramuscular; Male; M | 1973 |
Prevention of alcohol withdrawal seizures: the roles of diphenylhydantoin and chlordiazepoxide.
Topics: Alcoholism; Anticonvulsants; Chlordiazepoxide; Electroencephalography; Ethanol; Humans; Neurons; Phe | 1973 |
Infants exposed in utero to antiepileptic drugs. A prospective study.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Amitriptyline; Amniotic Fluid; Anticonvulsants; Chro | 1974 |
Failure of diphenylhydantoin to prevent alcohol withdrawal convulsions in mice.
Topics: Animals; Chloral Hydrate; Ethanol; Humans; Male; Mice; Mice, Inbred ICR; Phenytoin; Pyrazoles; Seizu | 1974 |
Modification of the morphine withdrawal syndrome in rats.
Topics: Animals; Humans; Male; Morphine Dependence; Phenytoin; Rats; Rats, Inbred Strains; Substance Withdra | 1974 |
Effects of diphenylhydantoin (Dilantin) withdrawal on non-epileptics: preliminary report.
Topics: Adult; Aged; Electroencephalography; Epilepsy; Humans; Middle Aged; Phenytoin; Substance Withdrawal | 1970 |
Diphenylhydantoin sodium (Dilantin) withdrawal in non-epileptics.
Topics: Adolescent; Adult; Aged; Electroencephalography; Female; Humans; Male; Middle Aged; Phenytoin; Subst | 1971 |
Is diphenylhydantoin effective in treatment of alcohol withdrawal?
Topics: Chloral Hydrate; Ethanol; Humans; Hypnotics and Sedatives; Paraldehyde; Phenytoin; Promazine; Substa | 1972 |
Diphenylhydantoin for treatment of alcohol withdrawal syndromes.
Topics: Administration, Oral; Alcoholism; Humans; Phenytoin; Substance Withdrawal Syndrome | 1971 |
Diphenylhydantoin and alcohol withdrawal.
Topics: Alcoholism; Diazepam; Drug Synergism; Humans; Phenytoin; Substance Withdrawal Syndrome | 1971 |
Diphenylhydantoin in alcohol withdrawal.
Topics: Administration, Oral; Alcoholism; Humans; Injections, Intramuscular; Phenytoin; Substance Withdrawal | 1971 |
Diphenylhydantoin in the treatment of alcohol withdrawal.
Topics: Alcoholic Intoxication; Humans; Phenytoin; Psychoses, Alcoholic; Substance Withdrawal Syndrome | 1971 |
Chlormethiazole and trifluoperazine in alcohol withdrawal.
Topics: Alcoholism; Chlormethiazole; Coma; Depression; Feeding and Eating Disorders; Female; Headache; Human | 1969 |
A new method for treatment of barbiturate dependence.
Topics: Barbiturates; Chlordiazepoxide; Diazepam; Heroin; Humans; Meprobamate; Pentobarbital; Phenobarbital; | 1970 |
Significance of seizures in patients receiving psychotropic drugs.
Topics: Adult; Drug Hypersensitivity; Epilepsy; Humans; Male; Meprobamate; Phenytoin; Schizophrenia; Seizure | 1965 |